UBS reiterates buy rating on Moderna stock, maintains $70 price target
PositiveFinancial Markets

UBS has reaffirmed its buy rating on Moderna's stock and maintained a price target of $70. This endorsement reflects confidence in Moderna's future performance.
Editor’s Note: This matters because a strong buy rating from a major financial institution like UBS can influence investor sentiment and potentially drive the stock price higher, benefiting shareholders.
— Curated by the World Pulse Now AI Editorial System